Publications
Tuberculosis screening in migrants to the EU/EEA and UK
2023
Eur Respir J
Köhler N, Vasiliu A, Mandalakas AMM et al
DOI:
10.1183/13993003.01230-2023
Tuberculosis in foreign-born persons in Europe
2023
Euro Surveill
Vasiliu A, Köhler N, Altpeter E et al
DOI:
10.2807/1560-7917.ES.2023.28.42.2300051
Performance of QuantiFERON-TB Gold Plus assays in paediatric tuberculosis: a multicentre PTBNET study
2023
Thorax
Buonsenso D, Noguera-Julian A, Moroni R et al
DOI:
10.1136/thorax-2022-218929
Relative cost of multidrug-resistant tuberculosis medicines in Europe.
2023
Int J Tuberc Lung Dis.
Günther G, Guglielmetti L, Leu C, van Leth F, Lange C for the TBnet.
DOI:
10.5588/ijtld.23.0026.
Relative cost of multidrug-resistant tuberculosis medicines in Europe.
2023
Int J Tuberc Lung Dis
Günther G, Guglielmetti L, Leu C et al
DOI:
10.5588/ijtld.23.0026
Predictive performance of interferon-gamma release assays and the tuberculin skin test for incident tuberculosis: an individual participant data meta-analysis.
2023
EClinicalMedicine
Hamada Y, Gupta RK, Quartagno M et al
DOI:
10.1016/j.eclinm.2022.101815
Clinical implications of molecular drug resistance testing for Mycobacterium tuberculosis: a 2023 TBnet/RESIST-TB consensus statement.
2023
Lancet Infect Dis
Domínguez J, Boeree MJ, Cambau E et al
DOI:
10.1016/S1473-3099(22)00875-1
Clinical implications of molecular drug resistance testing for Mycobacterium tuberculosis: a 2023 TBnet/RESIST-TB consensus statement.
2023
Lancet Infect Dis
Domínguez J, Boeree MJ, Cambau E et al.
DOI:
10.1016/S1473-3099(22)00875-1.
Availability and costs of medicines for the treatment of tuberculosis in Europe.
2023
Clin Microbiol Infect.
Günther G, Guglielmetti L, Leu C et al
DOI:
10.1183/13993003.00388-2022
Availability and costs of medicines for the treatment of tuberculosis in Europe.
2023
Clin Microbiol Infect
Günther G, Guglielmetti L, Leu C, Lange C, van Leth F for the TBNET*
DOI:
10.1016/j.cmi.2022.07.026.
Rifapentine access in Europe: growing concerns over key tuberculosis treatment component.
2022
Eur Respir J
Guglielmetti L, Günther G, Leu C et al
DOI:
10.1183/13993003.00388-2022
Co-administration of treatment for rifampicin-resistant TB and chronic HCV infection: A TBnet and ESGMYC study.
2022
J Infect
Tunesi S, Dû DL, Gualano G, et al.
DOI:
10.1016/j.jinf.2022.03.004
Safety and Outcomes of Amikacin Liposome Inhalation Suspension for Mycobacterium abscessus Pulmonary Disease: A NTM-NET.
2022
Chest
Zweijpfenning HSM, Chiron R, Essink S, et al.
DOI:
10.1016/j.chest.2022.01.015
Meningitis Study Group. Treatment and outcome in children with tuberculous meningitis - a multi-centre Paediatric Tuberculosis Network European Trials Group study
2021
Clin Infect Dis
Thee S, Basu Roy R, Blázquez-Gamero D, et al.
DOI:
10.1093/cid/ciab982
The ability of the neonatal immune response to handle SARS-CoV-2 infection.
2021
Lancet Child Adolesc Health
Götzinger F, Santiago-Garcia B, Fumadó-Pérez V, et al.
DOI:
10.1016/S2352-4642(21)00002-X